Sandu Pharmaceuticals Ltd (SANDUPHQ) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sandu Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Approval of Unaudited ....
Intimation · 14 Nov 2026, 5:30 am
Sandu Pharmaceuticals Board Meeting Scheduled for 14th Nov'26 to Approve Q2 Results Sandu Pharmaceuticals Limited has scheduled a meeting of its Board of Directors on 14th Nov'26 to consider and approve the standalone unaudited financial results for the quarter ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed for directors, officers, and designated employees from 1st Oct'26 and will remain shut until 48 hours post the public announcement of the quarterly results.
Intimation about change in name of Director from Dr Neeti Madan Kapre to Dr Neeti Gupta
Others (Uncategorized) · 09 Oct 2026, 5:10 pm
Sandu Pharmaceuticals Reports Name Change of Independent Director Dr Neeti Gupta Sandu Pharmaceuticals Limited has informed exchanges under Regulation 30 of SEBI LODR that Non-Executive Independent Director Dr Neeti Madan Kapre (DIN: 06801264) has changed her name to Dr Neeti Gupta consequent upon her marriage, as of 9th Oct'26. The company confirmed there are no changes to her designation, directorship, or DIN.
Intimation to the holders of Physical Securities to furnish PAN and KYC details
Others (Uncategorized) · 30 Sept 2026, 5:48 pm
Sandu Pharmaceuticals Issues KYC and Demat Compliance Notice to Physical Shareholders Sandu Pharmaceuticals has dispatched reminder notices on 29th Sep'26 to physical security holders to submit mandatory PAN, KYC, bank account, and signature details to its RTA, MUFG Intime India Private Limited. Failure to provide complete information restricts dividend payouts exclusively to electronic mode post-1st Apr'24. Additionally, the company highlighted SEBI's one-year special re-lodgement window for defective pre-Apr'19 transfer deeds, operational from 5th Feb'26 to 4th Feb'27, under which processed shares will be issued solely in dematerialized form.
1. Redesignation of shri Balram Viswanathan (DIN :10245195)as Chairman and Managing Director of the company. 2.Appointment of Dr Smt Neeti Kapre (DIN:06801264)as Non Executive Independent Director
Change in Management · 12 Sept 2026, 9:46 pm
Sandu Pharmaceuticals Approves Key Board Appointments at 41st AGM Sandu Pharmaceuticals Limited announced that shareholders approved key board appointments at the 41st AGM on 11th Sep'26. Shri Balram Viswanathan has been redesignated as Chairman and Managing Director for a 3-year term effective 11th Jul'26. Additionally, Dr. Neeti Madan Kapre has been appointed as a Non-Executive Independent Director for a 5-year term, effective 11th Jul'26, not liable to retire by rotation. Neither appointee is related to any director, key managerial personnel, or promoter, nor debarred by SEBI.
Appointment of M/s Dave & Dave Chartered Accountant as Statutory Auditor of the Company approved by shareholders in 41st Annual General Meeting
Change in Auditor · 12 Sept 2026, 8:44 pm
41st Annual General Meeting scrutinizers Report
Annual General Meeting · 12 Sept 2026, 8:25 pm
Proceedings of the 41st Annual General Meeting held on Friday 11th september 2026 at 04:30 pm
Annual General Meeting · 12 Sept 2026, 12:59 am
Letters to shareholders on annual report weblink whose email ids are not registered with the company/RTA
Annual Report · 19 Aug 2026, 11:11 pm
41st Annual Report of Sandu Pharmaceuticals Limited
Others (Uncategorized) · 19 Aug 2026, 11:08 pm
Intimation about Annual General Meeting
Annual General Meeting · 19 Aug 2026, 11:03 pm
approval of material related party transactions subject to approval of shareholder
Others (Uncategorized) · 12 Aug 2026, 12:11 am
Sandu Pharma Q1'27 Results: Key Board Decisions on Dividend, Auditors Sandu Pharmaceuticals reported Q1'27 Profit After Tax at ₹22.82 lakhs, up from ₹22.33 lakhs YoY, while Revenue from Operations declined to ₹1638.88 lakhs from ₹1669.90 lakhs YoY. The board approved the unaudited results for the quarter ended 30 Jun'26. A dividend for FY26 was proposed, with a record date set for 04 Sep'26. The 41st AGM is scheduled for 11 Sep'26 via video conference. Additionally, the board recommended the appointment of M/s. Dave & Dave as statutory auditors for a five-year term.
statement of deviation and utlisation of funds for q ended 30.06.2026
Others (Uncategorized) · 12 Aug 2026, 12:08 am
Sandu Pharma: No Deviation in Preferential Issue Fund Utilization for Q1'27 Sandu Pharmaceuticals reports no deviation or variation in utilizing funds from its three preferential issue tranches for the quarter ended 30th Jun'26. The funds, raised for capex and working capital, were used as intended. Tranche 1 (Rs 2.64 Cr) and Tranche 2 (Rs 1.38 Cr) are fully utilized. From Tranche 3 (raised 14th Jul'22), Rs 46.56 lakh of the Rs 1.32 Cr raised has been utilized. The Audit Committee has reviewed and approved the statement, confirming adherence to the original objectives.
Appointment of M/s Dave & Dave Chartered Accountant as statutory auditor subject to approval of the shareholder
Change in Management · 11 Aug 2026, 11:45 pm
Sandu Pharma Q1FY27 Results, Dividend Record Date & Auditor Appointment Sandu Pharmaceuticals reported Q1FY27 results on 11 Aug'26, with PAT at ₹22.82 lakhs, up 2.2% YoY. Total income fell 1.9% YoY to ₹1,640.62 lakhs. The Board declared a dividend for FY26, setting a record date of 4 Sep'26. It also approved the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a five-year term, subject to shareholder approval at the AGM on 11 Sep'26. Other agenda items included approval of FY26 reports and related party transactions.
Intimation about the date of the annual General Meeting
Annual General Meeting · 11 Aug 2026, 11:37 pm
Intimation about the Record date
Others · 11 Aug 2026, 11:35 pm
Sandu Pharma Q1 Results, Dividend Record Date & Auditor Appointment Sandu Pharmaceuticals reported Q1'27 results with Profit After Tax at ₹22.82 lakhs, up from ₹22.33 lakhs YoY. Revenue from operations stood at ₹1,638.88 lakhs, a slight decline from ₹1,669.90 lakhs YoY. The board set a record date of 4th Sep'26 for the FY26 dividend and approved the 41st AGM for 11th Sep'26. Additionally, the board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a five-year term, subject to shareholder approval.
Outcome and results of the Board Meeting dated 11.08.2026
Outcome · 11 Aug 2026, 11:29 pm
Sandu Pharma Q1 Results, Dividend Record Date, and New Auditor Appointment Sandu Pharmaceuticals reported Q1 FY27 standalone PAT at ₹22.82 lakhs, up 2.2% YoY from ₹22.33 lakhs but down significantly QoQ. Revenue from operations declined 1.9% YoY to ₹1,638.88 lakhs. The board approved the unaudited results and declared 4th Sep'26 as the record date for the FY26 dividend. Additionally, the board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a five-year term, subject to shareholder approval at the AGM on 11th Sep'26.
Unaudited Financials For ended 30.06.2026
Financial Result · 11 Aug 2026, 11:16 pm
Sandu Pharma Q1FY27 Results, Dividend Record Date & Auditor Appointment Sandu Pharmaceuticals reported Q1FY27 results for the period ended 30 Jun'26, with PAT at ₹22.82 lakhs versus ₹22.33 lakhs YoY. Revenue from Operations declined 1.9% YoY to ₹1,638.88 lakhs. The board approved the annual report for FY26 and set 4 Sep'26 as the record date for the proposed dividend. The company also approved the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a five-year term, subject to shareholder approval at the AGM on 11 Sep'26.
Outcome of the Board Meeting 11.08.2026
Outcome · 11 Aug 2026, 11:09 pm
Sandu Pharma Q1FY27 Results, Dividend Record Date, and New Auditor Appointment Sandu Pharmaceuticals reported Q1FY27 results on 11 Aug'26 with profit after tax at ₹22.82 lakhs, a 2.2% YoY increase. Revenue from operations stood at ₹1,638.88 lakhs, a 1.9% YoY decline. The board also approved the FY26 dividend proposal, setting a record date of 4 Sep'26. Additionally, the board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a five-year term, subject to shareholder approval at the AGM on 11 Sep'26.
Outcome of the Board Meeting
Outcome · 11 Aug 2026, 10:54 pm
Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 1,639 (-1.9% YoY | -2.8% QoQ) ■ EBITDA: 53.7 (+2.2% YoY | -6.3% QoQ) ■ EBITDA Margin (%): 3.3 (+13 bps YoY | -12 bps QoQ) ■ PAT: 22.8 (+2.2% YoY | +425.8% QoQ) ■ EPS (INR): 0.37 (+60.9% YoY | +825.0% QoQ)
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve 1.To consider and approve ....
Intimation · 11 Aug 2026, 5:30 am
Sandu Pharma Board to Approve Q1FY27 Results on 11th Aug'26 Sandu Pharmaceuticals (BSE: 524703) has scheduled a Board of Directors meeting on 11th Aug'26 to consider and approve the standalone unaudited financial results for the quarter ended 30th Jun'26. In compliance with insider trading regulations, the trading window for designated persons has been closed from 01st Jul'26 and will reopen 48 hours after the financial results are publicly announced. This action is pursuant to SEBI's Listing Obligations and Disclosure Requirements Regulation 2015.
Reconstitution of Committees of Board-Audit/Nomination/Stakeholders
Others (Uncategorized) · 11 Jul 2026, 11:06 pm
Sandu Pharma Reshuffles Board Following MD's Demise, Appoints New Director Following the demise of Managing Director Shri Umesh B. Sandu on 19th Jun'26, Sandu Pharmaceuticals has made key leadership changes. Effective 11th Jul'26, Shri Balram Viswanathan has been redesignated from Chairman and Non-Executive Independent Director to Chairman and Managing Director for a three-year term. Concurrently, Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director for a five-year term. The company also announced the reconstitution of its Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees to reflect these changes.
1.Appointment of Dr Neeti Madan Kapre (DIN:06801264) as additional Non Executive Independent Director of the Company 2.Redesignation of Shri Balram Viswanathan (DIN: 10245195) as Chairman ....
Change in Management · 11 Jul 2026, 11:02 pm
Sandu Pharma Appoints New MD and Independent Director Amid Board Reshuffle Following the demise of MD Shri Umesh B. Sandu on 19th Jun'26, Sandu Pharmaceuticals announced a leadership transition. Effective 11th Jul'26, Chairman Shri Balram Viswanathan has been redesignated as Chairman and Managing Director for a three-year term. Concurrently, the Board appointed Dr. Neeti Madan Kapre as an Additional Non-Executive Independent Director for a five-year term until 10th Jul'31. The company has also reconstituted its Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees to reflect these changes.
Outcome of the Board Meeting dated 11.07.2026
Outcome · 11 Jul 2026, 10:59 pm
Sandu Pharma Appoints New MD and Independent Director Amid Board Reshuffle Following the demise of MD Umesh B. Sandu, the Board has redesignated Shri Balram Viswanathan from Chairman & Non-Executive Independent Director to Chairman & MD for a three-year term starting 11th Jul'26. Additionally, Dr. Neeti Madan Kapre has been appointed as an Additional Non-Executive Independent Director for a five-year term. The company also reconstituted its Audit, Nomination & Remuneration, and Stakeholders' Relationship committees to reflect these leadership changes. The Vigil Mechanism Policy was revised accordingly.
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2026 ,inter alia, to consider and approve 1. To place on record ....
Intimation · 11 Jul 2026, 5:30 am
Sandu Pharma Board to Appoint New MD Post Demise of Umesh B. Sandu Sandu Pharmaceuticals has scheduled a Board Meeting on 11th Jul'26 to appoint a new Managing Director following the demise of Shri Umesh B. Sandu on 19th Jun'26. The agenda also includes the potential appointment of an additional Independent Director and the reconstitution of board committees. Concurrently, the company announced the closure of its insider trading window from 01st Jul'26 until 48 hours after the declaration of financial results for the quarter ending 30th Jun'26, as per SEBI regulations.
demise of Shri Umesh Sandu, Managing Director (DIN:01132141) revised disclosure
Others (Uncategorized) · 20 Jun 2026, 4:19 pm
Sandu Pharmaceuticals MD & Promoter Shri Umesh Sandu Passes Away Sandu Pharmaceuticals announced the sudden demise of its Managing Director and Promoter, Shri Umesh Sandu, on 19th Jun'26. Consequently, he ceases to be a Member of the Audit Committee and Stakeholders Relationship Committee. Shri Sandu held 13,88,693 shares in the company. The unexpected passing of the key managerial person creates a significant leadership vacuum and potential uncertainty for the company's strategic direction. The company has not yet announced succession plans.